For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

1st Jul 22

Pharmaxis Strengthens Clinical Development Oncology Capability with The Appointment of Dr Jana Baskar as Chief Medical Officer

Pharmaxis Limited (ASX:PSX), a clinical stage drug development company developing novel therapies to treat inflammatory and fibrotic diseases, is pleased to announce the appointment of Dr Jana Baskar to the role of Chief Medical Officer.

Dr Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies.

“We are delighted to welcome Dr Baskar to Pharmaxis, where his deep experience leading clinical programs will be an asset to the continued advancement of our pipeline,” commented Gary Phillips, Chief Executive Officer of Pharmaxis. “Dr Baskar brings significant oversight, clinical development and strategic expertise, having previously guided numerous programs through all phases of development. His extensive background and experience will be particularly valuable as the Company progresses its lead asset, PXS-5505, towards clinical proof of concept in myelofibrosis and other oncology indications.”

Read full media release - pdf
26th Apr 22

Pharmaxis Quarterly Shareholder Update and Investor Briefing

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 29 April 2022.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Friday 29 April 2022.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

The event is free to attend, and investors should register in advance using the following registration link:

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to:

Read full media release - pdf
1st Apr 22

Pharmaxis R&D Showcase Webinars - Recordings

Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods. 

Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers. 



Link to recording

Welcome and Introduction to Pharmaxis research and clinical development program

Michael Woods

Dr Wolfgang Jarolimek

Gary Phillips

The myelofibrosis landscape and MF-101

Dr Gabriela Hobbs (Massachusetts General Hospital)

Hepatocellular cancer and Rochester University investigator led study

Dr Paul Burchard (Rochester NY)

Pancreatic Cancer

Dr Tom Cox
(Garvan Sydney) 

Pharmaxis Q&A

Gary Phillips

Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)

A pdf of the presentations is available here.

Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.



Link to recording

Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology

Gary Phillips

The science of scarring and potential for LOX inhibition

Dr Mark Fear (UWA)

Clinical applications for LOX inhibition

Professor Fiona Wood (UWA)

Q&A with panel

Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)

A pdf of the presentations is available here.